Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...
Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback